Pre-made Varlilumab biosimilar ( Whole mAb, anti-CD27 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-614
Anti-CD27 therapeutic antibody (Pre-made Varlilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Varlilumab (INN; development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD27 therapeutic antibody (Pre-made Varlilumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia|
|Conditions Active||Malignant melanoma;Solid tumours;Non-Hodgkin's lymphoma;Renal cell carcinoma;Glioblastoma|
|Conditions Discontinued||Haematological malignancies;Prostate cancer;Breast cancer;Ovarian cancer;Glioma|